These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 25314777)
1. [Heterogeneity of acute myeloid leukemia with the translocation t(8;21)(q22;q22)]. Gritsaev SV; Martynkevich IS; Ziuzgin IS; Kariagina EV; Martynenko LS; Petrova EV; Tsybakova NIu; Ivanova MP; Kostroma II; Tiranova SA; Potikhonova NA; Abdulkadyrov KM Ter Arkh; 2014; 86(7):45-52. PubMed ID: 25314777 [TBL] [Abstract][Full Text] [Related]
2. Characteristics and prognostic factors of acute myeloid leukemia with t (8; 21) (q22; q22). Lai YY; Qiu JY; Jiang B; Lu XJ; Huang XJ; Zhang Y; Liu YR; Shi HL; Lu DP Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):733-40. PubMed ID: 16277833 [TBL] [Abstract][Full Text] [Related]
3. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573 [TBL] [Abstract][Full Text] [Related]
4. [Clinical analysis of acute myeloid leukemia with t(8;21) (q22;q22) and loss of Y chromosome]. Zhu CY; Yang H; Niu JH; Zhang Q; Xie XL; Wang LJ; Zhu HY; Yao ZL; Yu L; Jing Y Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):950-6. PubMed ID: 25130809 [TBL] [Abstract][Full Text] [Related]
5. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH; Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179 [TBL] [Abstract][Full Text] [Related]
6. Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21). Zhu HH; Jiang H; Jiang Q; Jia JS; Qin YZ; Huang XJ Leuk Res; 2016 May; 44():40-4. PubMed ID: 26994850 [TBL] [Abstract][Full Text] [Related]
7. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Schoch C; Haase D; Haferlach T; Gudat H; Büchner T; Freund M; Link H; Lengfelder E; Wandt H; Sauerland MC; Löffler H; Fonatsch C Leukemia; 1996 Aug; 10(8):1288-95. PubMed ID: 8709633 [TBL] [Abstract][Full Text] [Related]
8. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study. Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579 [TBL] [Abstract][Full Text] [Related]
9. Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients. Park SH; Chi HS; Cho YU; Jang S; Park CJ Leuk Res; 2013 Jul; 37(7):784-9. PubMed ID: 23528260 [TBL] [Abstract][Full Text] [Related]
10. [Clinical and experimental characteristics of 20 patients with acute myeloid leukemia with complex variant of t(8; 21)]. Xia J; Chen SN; Pan JL; Wang QR; Wu YF; Wang Y; Zhang J; Shen J; Xue YQ; Ruan CG Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):815-20. PubMed ID: 23998566 [TBL] [Abstract][Full Text] [Related]
11. [Studies of treatment strategy and prognosis on acute myeloid leukemia with chromosome 8 and 21 translocation]. Shi HX; Jiang B; Qiu JY; Lu XJ; Fu JF; Wang DB; Lu DP Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):481-4. PubMed ID: 16383240 [TBL] [Abstract][Full Text] [Related]
12. [The efficacy of high-dose cytarabine for patients with t(8;21) AML and with normal karyotype AML]. Li HY; Yue H; Wei XD; Zhu XH; Zhang YL; Zhang LN; Liu YY; Wang P; Fang BJ; Li YF; Song YP Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):110-2. PubMed ID: 18681312 [TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22). Bacher U; Schnittger S; Kern W; Trenn G; Weisser M; Haferlach T; Schoch C Cancer Genet Cytogenet; 2006 Jul; 168(2):172-4. PubMed ID: 16843110 [TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia (AML-M2) associated with variant t(8;21): report of three cases. Bae SY; Kim JS; Ryeu BJ; Lee KN; Lee CK; Kim YK; Lim CS; Cho Y; Choi CW; Ryu SW; Yoon SY Cancer Genet Cytogenet; 2010 May; 199(1):31-7. PubMed ID: 20417866 [TBL] [Abstract][Full Text] [Related]
15. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Kusec R; Laczika K; Knöbl P; Friedl J; Greinix H; Kahls P; Linkesch W; Schwarzinger I; Mitterbauer G; Purtscher B Leukemia; 1994 May; 8(5):735-9. PubMed ID: 7514242 [TBL] [Abstract][Full Text] [Related]
16. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Wakita S; Yamaguchi H; Miyake K; Mitamura Y; Kosaka F; Dan K; Inokuchi K Leukemia; 2011 Sep; 25(9):1423-32. PubMed ID: 21606963 [TBL] [Abstract][Full Text] [Related]
17. Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML. Nishii K; Usui E; Katayama N; Lorenzo F; Nakase K; Kobayashi T; Miwa H; Mizutani M; Tanaka I; Nasu K; Dohy H; Kyo T; Taniwaki M; Ueda T; Kita K; Shiku H Leukemia; 2003 Apr; 17(4):731-7. PubMed ID: 12682630 [TBL] [Abstract][Full Text] [Related]
18. Is translocation (8;21) a "favorable" cytogenetic rearrangement in acute myeloid leukemia? Fenaux P; Laï JL; Preudhomme C; Jouet JP; Deminatti M; Bauters F Nouv Rev Fr Hematol (1978); 1990; 32(3):179-82. PubMed ID: 2216701 [TBL] [Abstract][Full Text] [Related]
19. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833 [TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group. Klein K; Kaspers G; Harrison CJ; Beverloo HB; Reedijk A; Bongers M; Cloos J; Pession A; Reinhardt D; Zimmerman M; Creutzig U; Dworzak M; Alonzo T; Johnston D; Hirsch B; Zapotocky M; De Moerloose B; Fynn A; Lee V; Taga T; Tawa A; Auvrignon A; Zeller B; Forestier E; Salgado C; Balwierz W; Popa A; Rubnitz J; Raimondi S; Gibson B J Clin Oncol; 2015 Dec; 33(36):4247-58. PubMed ID: 26573082 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]